Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to evaluate 1. The microbiological response and clinical efficacy of SPR720 compared with placebo in participants with nontuberculous mycobacteria pulmonary disease (NTM-PD). 2. The safety and tolerability of SPR720 in a participants population with NTM- PD 3. The pharmacokinetic (PK) of SPR719, active moiety, following orally (po) administered prodrug SPR720 in a participant population with NTM-PD.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05496374
Study type Interventional
Source Spero Therapeutics
Contact Manoj Jivani
Phone 8572421591
Email MJivani@sperotherapeutics.com
Status Recruiting
Phase Phase 2
Start date December 14, 2022
Completion date October 2024